In this episode of the CEOLIVE.TV Investor Update Series we are joined again by Nano Dimension CEO, Amit Dror who discusses the company’s recent patent application for the 3D printing of human tissues and organs.
The company, through a collaboration with Accelta, is developing a new 3D printer and bio-inks capable of using stems cells to print bio-organic material, specifically tissues and organs from MRI’s and CT scans.
About Nano Dimension
Nano Dimension, founded in 2012, focuses on development of advanced 3D printed electronics systems and advanced additive manufacturing. Nano Dimension’s unique products combine three advanced technologies: 3D inkjet, 3D software and nanomaterials. The company’s primary products include the first 3D printer dedicated to printing multi-layer PCBs (printed circuit boards) and advanced nanotechnology-based conductive and dielectric inks.
“Multilayer, 3D inkjet PCB printing is an entirely new category of 3D printing designed specifically for the production of professional multilayer PCBs, and it eliminates the negative issues associated with outside manufacturing facilities. With Nano Dimension’s DragonFly 2020 3D Printer – a world’s first for printing multilayer circuit boards, users can build functional prototypes in-house (including the interconnections between layers) in a matter of hours.”
-Amit Dror, CEO of Nano Dimension, LTD
According to a video on CNET:
3D printing a circuit board gives you a couple of different advantages over the traditional method of sending it out to a manufacturing plant. The first one is that your intellectual property can stay safe and be produced in house. The second is the time it takes. Rather than a couple of weeks to get a prototype of a circuit board back for testing, this takes a couple of hours or even overnight.
Dragonfly 2020 uses a nano silver conductive ink and a proprietary dielectric ink for its printing. The product should be available on the market by the end of 2016. Meanwhile, pricing has yet to be disclosed.
Forward Looking Statements
This CEOLIVE.TV video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.
Neither CEOLIVE.TV or any of its principals currently owns or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, ceolive.tv/disclaimer.
CEOLIVE content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOLIVE content and productions, or other investor relations materials and presentations are subject to change. Neither CEOLIVE nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information is provided for informational or entertainment purposes only. CEOLIVE is not a registered broker-dealer or a registered investment advisor.